Efficacy and safety of percutaneous patent foramen ovale closure in patients with a hypercoagulable disorder. (25th November 2020)

• Record Type: Journal Article
• Authors: Ben-Assa, E; Herrero-Garibi, J; Cruz-Gonzalez, I; Elmariah, S; Al-Bawardy, R; Sakhuja, R; Lima, F.V; Mingming, N; Inglessis, I; Palacios, I.F
• Is Part Of: European heart journal. Volume 41:(2020)Supplement 2
• Publication Date: 2020-11-25
• Subjects: PFO/ASD Closure; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/ehjci/ehaa946.2656
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Background: Transcatheter closure of patent foramen ovale (PFO) in patients with cryptogenic stroke reduce the rate of recurrent events. Although presence of thrombophilia increases the risk for paradoxical emboli through a PFO, such patients were excluded from the large randomized studies. Purpose: To examine the effect of hypercoagulable state on clinical outcomes after PFO closure. Methods: We retrospectively analyzed data of 800 consecutive patients undergoing percutaneous PFO closure at the Massachusetts general hospital. We compared the safety and efficacy of the procedure in patients with and without a hypercoagulable state. Periprocedural treatment included 3 months of anticoagulation followed by low dose aspirin. Results: A hypercoagulable disorder was found in 239 patients (29.9%). There were no significant differences in baseline demographics, echocardiographic characteristics, procedural success rate, or complication rate between both groups. At median follow-up of 41.9 months there were no differences in the rate of stroke/transient ischemic attack (2.5% in non-hypercoagulable group vs. 3.4% in hypercoagulable group, log-rank test p=0.349). Survival analysis of composite outcome that included: ischemic neurologic event, reintervention and procedural or neurologic death did not show significant difference between groups (Log-rank p=0.122). Conclusion: Percutaneous PFO closure is a safe and effective therapeutic approach for patients with cryptogenic stroke and an underlying hypercoagulable state Funding Acknowledgement: Type of funding source: Public hospital(s). Main funding source(s): Research funds of the Massachusetts general hospital